Cryptic Epitopes Induce High-Titer Humoral Immune Response in Patients with Cancer

Eliane Fischer, Sebastian Kobold, Sascha Kleber, Boris Kubuschok, Erik Braziulis, Alexander Knuth, Christoph Renner and Andreas Wadle

*J Immunol* 2010; 185:3095-3102; Prepublished online 26 July 2010;
doi: 10.4049/jimmunol.0902166
http://www.jimmunol.org/content/185/5/3095

Supplementary Material

http://www.jimmunol.org/content/suppl/2010/07/23/jimmunol.0902166.DC1

References

This article cites 51 articles, 23 of which you can access for free at:
http://www.jimmunol.org/content/185/5/3095.full#ref-list-1

Subscription

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Cryptic Epitopes Induce High-Titer Humoral Immune Response in Patients with Cancer

Eliane Fischer,*# Sebastian Kobold,* Sascha Kleber,* Boris Kubuschok,‡ Erik Braziulis,§ Alexander Knuth,* Christoph Renner,*# and Andreas Wadle*#†

In search of novel markers for diagnosis, prognosis, and therapy of cancer, screening of rcDNA expression libraries with patient’s sera has been established as a valuable tool for identification of cancer-specific Ags. Interestingly, besides the expected humoral responses to annotated proteins, patients with cancer were frequently found to have serum Abs that bind to peptides without homology to known proteins. So far, the nature of these unconventional epitopes and their possible significance in tumor immunity have never been thoroughly investigated. In our study, we specifically analyzed humoral immune response toward such peptides in patients with pancreatic or breast cancer using yeast-displayed cDNA expression libraries derived from tumor tissue. A detailed analysis of the identified peptides revealed that they originated from translation of sequences outside annotated open reading frames and may derive from the use of alternative start codons or from DNA indel mutations. In several cases, the corresponding mRNA templates have a known association with cancer. In a final analysis, we were able to detect one of these tumor Ags in cancer tissue arrays by a selected Fab-Ab. We conclude that cryptic epitopes may elicit specific humoral immune responses in patients with cancer and thus play a role in immunologic surveillance. Due to the high prevalence of immune responses against some of the peptides, they may also be valuable markers for cancer diagnosis, prognosis, or therapy monitoring. The Journal of Immunology, 2010, 185: 3095–3102.

Patients with cancer exhibit humoral immune responses against Ags expressed in tumor tissue, detectable as high-titer IgGs in blood serum (1–6). Hence, cancer-specific autoantibodies have been exploited to identify novel targets for therapy (7), markers for more sensitive diagnostics of various cancers (8–10), or simply better understanding of tumor biology. Most prominently, the serological analysis of rcDNA expression libraries method led to the identification of >2000 annotated antigenic sequences that are collected in the Cancer Immunome Database (11) to date.

Originally based on prokaryotic expression, the serological analysis of rcDNA expression libraries method was adapted to a yeast display-based system to facilitate folding and allow post-translational modification of the expressed Ags (12–14), but also for efficient presentation of small peptides (15). We previously reported the use of rAg expressed on yeast surface technology for the discovery of novel Ags associated with breast cancer (16) and for the detection of autoantibodies to known cancer-testis Ags in patients with pancreatic cancer (17).

Over the years, we have identified a significant number of clones recognized by patient sera that were not encoded by known or postulated open reading frames (ORFs) and discarded them as potential artifacts. There is a growing body of evidence also reported by other authors indicating that specific humoral responses to cryptic epitopes can occur that were generated from cloning of putatively untranslated sequences into the expression system (8, 9). Despite their potential usefulness as biomarkers for various cancerous diseases, such cryptic epitopes are usually referred to as mimotopes (i.e., structures that mimic a structurally unrelated Ag), rather than real epitopes, and are not further investigated (8, 9). In consequence, little is known about their potential biological relevance in cancer immunity, although they could hold valuable information for a more holistic understanding of tumor-host interaction.

Still, there are virtually no data on humoral immune responses against actually proven cryptic epitopes. One exception is a study that describes the serological analysis of a cDNA library from microsatellite instability (MSI)-positive colon cancer cell lines (18). In this report, a patient with known MSI-positive colon cancer had a frameshift mutation in the coding region of CDX2, one of the identified Ags, and concomitantly showed an anti-CDX2 humoral response. In the patient’s serum, Abs against both neopeptides caused by the frameshift mutation and native epitopes of CDX2 were present. This is the first proof that tumor-specific peptides generated by MSI are involved in antitumor immune responses, possibly causing the better prognosis associated with MSI (19), and may, therefore, be useful for the development of new therapeutic approaches.

Although genetic inactivation of DNA mismatch repair leading to MSI is an elegant mechanistic explanation for the emergence of cancer-specific neopeptides, the latter may play a more general role in cancer immunity. Based on our previous serological analyses, we expect them to be present in a wide range of tumors. Therefore, we set out to systematically analyze antigenic cryptic epitopes from yeast-displayed cDNA libraries of breast and pancreatic cancer and provide an in-depth analysis of these unconventional epitopes.
Materials and Methods

Patients and samples

This study was approved by the local ethic committee (Ethikkommission der Ärztekammer des Saarlandes) and performed in accordance with the Declaration of Helsinki. After informed consent, serum samples were collected from 113 patients with inoperable or operable adenocarcinoma of the pancreas. In a proportion of patients (76%), tumor samples were obtained from pancreaticoduodenectomy (Whipple operation) or pancreatic-atectomy at the Saarland University Medical School (Homburg, Germany) between January 1997 and November 2000. To evaluate the specificity of the Ab responses for patients with cancer, tumor sera were compared with 63 sera from age- and sex-matched healthy donors and 18 sera from patients with acute or chronic pancreatitis. Furthermore, tumor and serum samples were obtained from 98 patients with operable breast cancer upon the primary definitive operation (mastectomy: 56 cases; lumpectomy: 59 cases; reductive tumor surgery: 5 cases) at the Department of Gynecology, University of Saarland Medical School (Homburg, Germany) between June 2001 and May 2002. In addition, 30 sera from women with autoimmune disease and 56 sera from age-matched healthy women were collected at the Department of Internal Medicine I, University of Saarland.

cDNA library construction

Total RNA was extracted from 15 adenocarcinoma or 15 breast cancer samples using the guanidium-thioisocyanate method as previously described (16). cDNA was synthesized from mRNA using the First Strand cDNA Synthesis Kit (2.0) (Invitrogen, Leiden, The Netherlands). cDNA synthesis was performed by the use of the Matchmaker Library Construction & Screening Kit (BD Biosciences, San Jose, CA) following the manufacturer’s instructions, and a modified PPD1 Vector (Invitrogen) was generated for cDNA library expression. The cDNA library was cloned by homologous recombination in the Smal linearized vector followed by a cotransformation into the competent Saccharomyces cerevisiae strain EBY100. Cultivation of yeast and induction of peptide expression was done as previously described (14, 17, 20).

Immunofluorescence staining for cell sorting

Patient sera were diluted 1:50 and two times preabsorbed on a yeast suspension (24 h at 4˚C) and then pelleted (1500 rpm, 5 min). Supernatants were used for immunofluorescence staining. The yeast cDNA library was divided in aliquots and stained with 20 different pools containing five single sera (each preabsorbed sera at 1:100 final dilution). Yeast cells were pelleted and washed three times in PBS/Tween 0.1%. Autoreactive binding IgGs were detected by the use of an anti-human IgG1 Ab, directly conjugated with PE (Jackson ImmunoResearch Laboratories, Suffolk, U.K.) as previously shown (14, 17, 20). Single cells were sorted by flow cytometry (DakoCytomation/Moffo, Hamburg, Germany). Parameters for the sorting procedure were established by double staining of a yeast clone expressing NY-ESO-1 using an anti-His Ab and polyclonal patient sera. The procedure was performed as previously described (17).

Plasmid DNA isolation from monoclonal yeast culture

The isolation of plasmid DNA was performed using the GFX Micro Plasmid Prep Kit (GE Healthcare, Munich, Germany). In addition to the manufacturer’s protocol, cell lysis was improved by addition of glass beads (Sigma-Aldrich, Munich, Germany) to the cell pellet (in a ratio of 1:2) and vigorous vortexing (30 min before isolation protocol). Extraction, amplification, and electrophoresis were performed as previously described (14, 17, 20). Inserts were sequenced using the Sequitherm EXCEL II DNA Sequencing Kit (Epigenetic Biotechnologies, Madison, WI) and a LI-COR DNA Binding Kit (LI-COR Biosciences, Munich, Germany). Sequences were assigned with the National Center for Biotechnology Information BLASTN Database (Bethesda, MD) (21).

Serological analysis by flow cytometry

Detection of immunological response at a single sera level was performed by the use of 30,000 yeast cells displaying the selected peptides on their cell surface. All preabsorbed sera were diluted 1:100, and staining was performed as described (14, 17, 20). FACs analysis was done using the WinMDI 2.8 software. Ratios of the mean fluorescence of Ag expressing yeast and mock-transformed yeast were calculated for each serum. A serum was considered responsive when the ratio exceeded the mean plus 3SD of the healthy control group’s ratio by >5 times the SD (22). The significance of the association of positive immune response with disease was determined by Fisher’s exact test.

Serological analysis by ELISA

Serum reactivity on synthetic peptides was assessed by ELISA as previously described (23). The sera were used in a series of different dilutions (1:50–20,000, 100 µl/well), and data were collected by measuring the absorption at 450 nm with a microplate reader (Wallac Victor 2, PerkinElmer, Wellesley, MA).

Selection of Fab-Abs to the novel identified Ags

Selection, purification, and assessment of specific Fab-Abs were entirely performed by standard methods (24). Briefly, a phage library was used expressing a large nonimmune, human Fab repertoire, containing 1.45 × 10^12 different Ab fragments. Phages (1.8 × 10^5) were preabsorbed (1 h, room temperature) in 2% nonfat dry milk PBS with streptavidin-coated paramagnetic beads (Dyna, Oslo, Norway) and subsequently immobilized on 96-well plates (1 h) with decreasing concentrations (3) of biotinylated M026 peptide (Peptides and Elephants, Potsdam, Germany: 300, 100, 20, and 5 nM). Streptavidin-coated beads were then added and mixed with constant rotation (15 min, room temperature). After eight washes cycles with 0.1% Tween-PBS and two additional washes with PBS, bound phages were eluted with 100 mM triethylamine and neutralized with Tris-HCl (pH 7.2). Phages were used to infect Escherichia coli strain TG1 (30 min, 37°C) and bacteria were grown overnight (30°C) on agar. The diversity of the selected Abs was determined by DNA sequencing. To confirm the reactivity of the selected Fab-Abs, 100 µl was used at a concentration of 10 µg/ml for yeast clone staining. All staining steps were done at room temperature, and each sample was washed twice with PBS/Tween 0.1%. Bound Fab-Abs were detected by a biotinylated anti-human Fab-Ab (1:200; Jackson Immunoresearch Laboratories) and streptavidin-PE (1:300; Jackson Immunoresearch Laboratories).

ELISA with phage and purified Fab-Abs

The specificity of individual binders displayed on phage surface and soluble Fab-Abs was assessed by ELISA with coated biotinylated peptides as described (25). Recombinant soluble Fab-Abs were purified from E. coli periplasmic fraction as shown earlier (24). Bound Fab molecules were detected by the murine anti-Myc Ab 9E10 (Roche, Mannheim, Germany) and an HRP-conjugated anti-mouse IgG (DakoCytomation). Bound phage particles were detected by the Ab M13 recognizing the polyprotein (Amersham Pharmacia Biotech, Uppsala, Sweden) and an HRP-conjugated anti-mouse IgG (DakoCytomation). Detection was performed using tetramethylbenzidine reagent (Sigma-Aldrich).

Fluorescence microscopy

Fab B1 was modified by 3’-terminal biotin tag cloning allowing for in vivo biotinylation at the C-terminal end (24, 26). Biotinylated Fabs were tetramizerized using Strept-A-FITC (Jackson Immunoresearch Laboratories) (24, 26). Prior to immunostaining, tissue arrays with 90 breast cancer tissues and 10 normal breast tissue controls (Cybrdi, Rockville, MD) were deparaffinized in xylene (four times, 2 min each), followed by 1 min washes in EtOH 100% (two times), EtOH 95%, EtOH 80%, EtOH 70%, and finally water. After blocking in PBS containing 2% BSA (Sigma-Aldrich) for 30 min, samples were incubated with the tetramerized Abs (1 h, room temperature) and then washed three times in PBS for 5 min. For nuclear staining, sections were incubated for 5 min in PBS containing 1 µg/ml Hoechst 33342 (Sigma-Aldrich) and then washed twice for 5 min in PBS. Finally, the samples were mounted with Dako mounting solution (DakoCytomation) containing 25 mg/ml DABCO antiquenching agent (Sigma-Aldrich). Fluorescence microscopy was performed using a Nikon Eclipse TE2000-U inverted microscope equipped with Hoechst and FITC filter sets (Nikon, Egg, Switzerland). Images were processed with Photoshop 7.0 (Adobe Systems, Munich, Germany).

Identification of yeast-displayed epitopes for M026-Ag specific Fab-Ab

cDNA-expressing yeast libraries were cultured and peptide expression induced. A total of 25–50 µl yeast culture (OD 2-3) and 20 µl magnetic beads (Dynabeads M-280 and streptavidin 112.06G, Invitrogen) were washed and surface blocked by milk powder/PBS suspension (4%, 6 h, 4°C). Subsequently, the yeast library was incubated with a biotinylated M026 Fab-Ab (B1) in a final concentration of 10 µg/ml (15 min, 4°C). Then, labeled yeast cells were captured with magnetic streptavidin beads (1% buffer) under PBS (2 h, 4°C) and separated by magnetic cell sorting. Unspecifically bound cells were removed by stringent washing (six times with PBS-Tween 0.1%, six times with PBS-Tween 0.3%, two times with PBS). After rigorous vortexing, selected clones were plated and incubated...
at 30˚C. This process was repeated two times. From monoclonal yeast cultures, pYD1-cDNA sequencing was performed as described earlier.

**Results**

**Generation and sorting of pancreatic and breast cancer cDNA libraries**

Two cDNA libraries from pancreatic adenocarcinoma and breast cancer tissue samples were cloned into the modified yeast display vector pYD1Rec. This vector allows expression of cDNA products as Aga2p fusion proteins on yeast surface. The transformed yeast libraries yielded ∼10^6 primary transformants (670,000 CFU/μl).

Randomly picked clones were analyzed by insert sequencing (data not shown) and the size of cloned fragments determined by cDNA restriction enzyme digests varied from 100–1700 bp (Fig. 1A). Next, the libraries were enriched for yeast clones recognized by autoreactive Abs in the sera of patients with pancreatic and breast cancer. In the current study, we aimed to selectively search for yeast clones that react with the sera of patients with cancer and display an epitope derived from a cryptic sequence on yeast surface. Therefore, translated Aga2p fusion proteins without an in-frame C-terminal Penta-His-tag were selected. Following this strategy, we deselect clones with a continuous reading frame from the Aga2p protein to the His-tag. Detector settings for flow cytometry were deduced using a His-tagged NY-ESO-1–expressing yeast clone stained with a reactive patient’s serum (Fig. 1B).

Upon fluorescence staining with serum pools, 0.07% of the total library was selected by high-speed cell sorting (Fig. 1C, boxed portion of left panel). Despite the fact that only a minority of all clones expresses a C-terminal His-tag, an equal fraction of these clones was identified as cancer-specific Ags by serial serological analysis. Immune reactivity of serum samples from patients with cancer (A), healthy donors (B), and control groups (C) to 12 yeast clones expressing cryptic epitopes. Serum reactivity is indicated as standard deviations from the mean of the healthy donor group’s response as determined by FACS analysis (Gmean ratio of fluorescence intensity on Ag expressing and mock-transfected yeast clones). The criterion for a positive immune response (mean + 5 SDs) is denoted by a horizontal line. Level of significance was determined by Fisher’s exact test and is indicated by asterisks.

\[ p < 0.05; \quad **p < 0.01; \quad ***p < 0.001. \]
were selectively recognized by patients with cancer to respective cryptic epitopes were further characterized. The surprisingly common immune responses of patients with cancer to some of the other candidates, albeit less frequently. The generally lower serum reactivity of the clones without C-terminal His-tag is expected, because a large part of the peptides displayed by these clones will be only artificially expressed on the yeast (e.g., by cloning artifacts), but will not be present in cells.

A total of 600 clones from a breast and a pancreatic cancer cDNA library were sorted, sequenced, and translated into corresponding peptide sequences of the Aga2p fusion proteins. The putative peptide length expressed on yeast surface ranged between 11 and 250 aa and was confirmed by Western blot analysis of the Aga2p fusion proteins (data not shown). A high fraction of the peptides were identified as cryptic epitopes, or more precisely as peptide sequences without homology to known proteins. They mainly originated from cDNAs that were cloned out of frame to the linker protein or from 3’ and 5’ untranslated region (UTR) sequences fused to the Aga2p protein. Besides that, some epitopes were generated by cloning of short genomic DNA fragments.

Identification of cancer-related Ags

To identify cryptic epitopes that are selectively immunogenic in patients with pancreatic or breast cancer, serial serological analysis of 99 patients with pancreatic cancer and 63 age- and sex-matched healthy donors or 98 patients with breast cancer and 56 age-matched healthy women were performed. Patients with acute chronic pancreatitis and autoimmune diseases were evaluated as a second control group in addition to healthy individuals. We found 12 peptides with a higher percentage of serological responses in the patient pool than in the control groups, in which a positive response exceeded the mean of the healthy donor group by >5 SDs (Fig. 2, Table I, Supplemental Data 1). Up to 16.2% of sera from tumor patients were reactive to the individual peptide-expressing yeast clones, whereas no healthy donors and only very few patients from control groups with inflammatory diseases exhibited IgG reactivities. For the clones M009, M026, M483.2, and P166, the number of positive responders within the group of patients with cancer was significantly higher than in the healthy control group, as determined by Fisher’s exact test. However, patients also exhibited strong immune responses to some of the other candidates, albeit less frequently. The surprisingly common immune responses of patients with cancer to cryptic epitopes were further characterized.

Characterization of cryptic epitopes

We were able to map the regions for 8 of the 12 cryptic epitopes that were selectively recognized by patients with cancer to respective RefSeq mRNAs (Fig. 3). The sequences of the remaining four clones were not attributable to RefSeq mRNAs but identified as genomic sequences.

Next, we elucidated whether there are mechanisms that could explain the existence of the displayed peptides, or at least parts thereof, in human cells. In principle, cryptic epitopes may derive from all levels of gene and protein expression, including the use of alternative reading frames, ribosomal frameshifting, or DNA mutations (Table II). Notably, the ACG triplet that was found upstream of the M026 sequence was in a strong Kozak context. The putative use of this alternative start codon results in the translation of a 65-aa peptide, and the C-terminal 14 aa are a −1 frameshifted product of the annotated ORF for metastasis-associated protein 2 (MTA2).

Another mechanism at the translational level that could potentially contribute to the expression of cryptic epitopes is ribosomal frameshifting, which can occur on prone sites. We searched for the corresponding characteristics of the cryptic epitope’s mRNA for the clones that were translated in alternative reading frames (P483.1, M004) by using the KnotInFrame algorithm to explain the existence of the displayed peptides, or at least parts thereof, in human cells. In principle, cryptic epitopes may derive from all levels of gene and protein expression, including the use of alternative reading frames, ribosomal frameshifting, or DNA mutations (Table II). Notably, the ACG triplet that was found upstream of the M026 sequence was in a strong Kozak context. The putative use of this alternative start codon results in the translation of a 65-aa peptide, and the C-terminal 14 aa are a −1 frameshifted product of the annotated ORF for metastasis-associated protein 2 (MTA2).

Another mechanism at the translational level that could potentially contribute to the expression of cryptic epitopes is ribosomal frameshifting, which can occur on prone sites. We searched for the corresponding characteristics of the cryptic epitope’s mRNA for the clones that were translated in alternative reading frames (P483.1, M004) by using the KnotInFrame algorithm to explain the existence of the displayed peptides, or at least parts thereof, in human cells. In principle, cryptic epitopes may derive from all levels of gene and protein expression, including the use of alternative reading frames, ribosomal frameshifting, or DNA mutations (Table II). Notably, the ACG triplet that was found upstream of the M026 sequence was in a strong Kozak context. The putative use of this alternative start codon results in the translation of a 65-aa peptide, and the C-terminal 14 aa are a −1 frameshifted product of the annotated ORF for metastasis-associated protein 2 (MTA2).

Another mechanism at the translational level that could potentially contribute to the expression of cryptic epitopes is ribosomal frameshifting, which can occur on prone sites. We searched for the corresponding characteristics of the cryptic epitope’s mRNA for the clones that were translated in alternative reading frames (P483.1, M004) by using the KnotInFrame algorithm to explain the existence of the displayed peptides, or at least parts thereof, in human cells. In principle, cryptic epitopes may derive from all levels of gene and protein expression, including the use of alternative reading frames, ribosomal frameshifting, or DNA mutations (Table II). Notably, the ACG triplet that was found upstream of the M026 sequence was in a strong Kozak context. The putative use of this alternative start codon results in the translation of a 65-aa peptide, and the C-terminal 14 aa are a −1 frameshifted product of the annotated ORF for metastasis-associated protein 2 (MTA2).
We next compared the patient’s immune response to the cryptic epitopes M026, P483.2, and P166 with the serum reactivity to the in-frame translated products. To this aim, we mutated the corresponding cDNAs for in-frame expression in yeast. Interestingly, six patients with pancreatic cancer indeed had reactive sera for the in-frame expressed product of P166 (Fig. 4C), one patient to IL15RA (P483.2) (Fig. 4D), whereas no reactive serum was identified for correctly expressed MTA2 (M026) in patients with breast cancer (data not shown).

Detection of M026

To detect cryptic epitopes in biological material, Ab Fab fragments specific for these products were selected by phage display technology. After three selection rounds, we isolated Fab-Ab B1, which specifically bound to the biotinylated peptide GHGGQHVPGGRLRLF (Fig. 5A). We tested whether the B1 Ab specifically binds to the GHGGQHVPGGRLRLF peptide sequence or if it is able to bind to other sequence-unrelated peptides displayed on the yeast surface. To this aim, we incubated the original library with the Fab-Ab and selected yeast clones by performing two rounds of selection. With this procedure, we enriched several additional clones, and all of these clones shared a common sequence at the C terminus of the displayed peptide (Table III, Supplemental Data 1). We therefore conclude that the binding of B1 to M026 is sequence-specific, and the epitope most probably includes the sequence GRLRL.

In vivo biotinylated B1 was tetramerized by streptavidin A and used for staining of a tissue array containing mammary gland carcinoma and healthy tissues by immunofluorescence. A cytoplasmic staining pattern could be observed in 4 out of 90 carcinoma tissues, whereas all normal tissue samples were negative (Fig. 5B, 5C). These results indicate the presence of the M026 epitope in human breast cancer tissue.

Discussion

In our thorough analysis of cDNA expression libraries with patient’s sera, the strongest and most prevalent immune reactions were observed toward epitopes lacking homology to any known proteins. Such epitopes are the products of sequences outside annotated ORFs (e.g., 3’ and 5’ UTRs of the mRNA or alternative

Table II.  Putative mechanisms that give rise to cryptic epitopes

<table>
<thead>
<tr>
<th>Putative Mechanism</th>
<th>Clone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upstream ORFs (alternative start codons)</td>
<td>M008, M026</td>
</tr>
<tr>
<td>Ribosomal frameshifting</td>
<td>Not found</td>
</tr>
<tr>
<td>DNA mutations</td>
<td>P483.1, P166, M081</td>
</tr>
<tr>
<td>Mimotopes (glycin-rich sequences)</td>
<td>M004, M009, M017</td>
</tr>
</tbody>
</table>

detect ~1 programmed frameshifts. However, we did not find evidence for ribosomal frameshifting to occur in these cases.

DNA mutations present a second source of cryptic epitopes by causing frameshifts by insertion or deletion of nucleotides or by affecting the genetic architecture (e.g., splice sites). We searched the Ensembl database for known single nucleotide polymorphisms on cDNA sequences. Interestingly, two sequences coding for cryptic epitopes were derived from mRNA regions with several identified indel mutations (P483.1, P166). The cDNA sequence of clone M081 also had deletion mutations. However, because all three sequences are not overlapping the ORF, the consequence of these mutations is unclear.

Finally, we found that some of the peptides contained repetitive, glycine-rich sequences. The immune reaction to these epitopes may be relatively unspecific. Thus, we classified them as mimotopes that may not be specifically recognized by patient’s sera, but instead mimic the structure of unrelated epitopes.

Next, we characterized the most immunogenic candidates, P166 and M026, in more detail (Fig. 4A, 4B). To this end, we used synthetic peptides with overlapping sequences for each Ag and tested binding of the highest responsive sera by ELISA. The C-terminal part of Ag P166 (VSLLYPCCEVPSPRGW) was shown to contain the epitope recognized by the patient’s sera, whereas no reactivity was observed for the N-terminal part HGRTGTTG-VSLLYPC (data not shown). Likewise, the peptide covering the C-terminal part of Ag M026 (GHGGQHVPGGRLRLF), but not the N-terminal, glycine-rich sequence (GAGGGGGNGHGG-QH), was recognized by the highest responsive breast cancer patient’s sera (data not shown). Down to a 1000-fold dilution of the highest responsive sera, reactivity was still detectable on the synthetic peptides by ELISA (Fig. 4B) or FACS (Fig. 4A) analysis using the respective yeast clones.

**FIGURE 4.** Analysis of serum reactivity to cryptic epitopes. A, FACS analysis of serial dilutions of an immune responsive pancreatic cancer patient serum on yeast clone P166 (●), yeast clone M026 (○), and a nonresponsive serum on yeast clone P166 (□). B, Serial dilution of an immune-responsive pancreatic cancer patient serum on synthetic peptide VSLLYPCCEVPSPRGW (●), peptide GHGGQHVPGGRLRLF (○), and a nonresponsive serum on peptide VSLLYPCCEVPSPRGW (□) as determined by ELISA. Immune reactivity of serum samples from patients with cancer to yeast clones expressing frameshifted peptides versus the in-frame cloned ORF product. Positive immune responses are defined by the dotted lines (mean + 5 SDs from the healthy donors group). C, P166 versus product of MMP-11 downstream ORF. D, P438.2 versus IL-15RA.

The Journal of Immunology 3099
reading frames as a direct result of the cDNA cloning procedure. This phenomenon is often explained with the occurrence of mimotopes (i.e., peptides that mimic an Ag [e.g., a tumor-specific glycosylation pattern] but are not homologous at the sequence level) (9, 10). In consequence, neither the origin nor the potential biological relevance of these peptides has been investigated further. Although we do not categorically exclude this hypothesis, we provide in this study evidence that at least some cryptic epitopes could actually be expressed in cancer tissue.

From the pancreatic cancer library, we isolated clone P166 displaying a peptide derived from the mRNA of matrix metalloproteinase 11 (MMP-11). Transcription of MMP-11 is significantly increased in pancreatic cancer tissue, where the protein is expressed on both tumor epithelial cells and the adjacent stroma (27, 28). A second example of a cancer-related Ag is a peptide derived from a frameshifted sequence of the MTA2. Overexpression of the latter leads to estrogen-independent growth of breast cancer cells (29). The cryptic epitope putatively arises by use of an upstream alternative start codon. We found a high incidence of humoral immune responses in patients with breast cancer to this Ag with 16.2% positive serum samples. We selected a Fab-Ab specific for the cryptic epitope that was able to stain breast cancer tissue but not normal tissue. In-frame cloning of the MTA2 protein, however, did not reveal autoimmunity of the patients with cancer to the correctly expressed protein.

Furthermore, we identified sera autoreactivity to a cryptic epitope mapped to the mRNA of a 5’ UTR splice variant of the zinc finger and BTB domain containing protein 4 (ZBTB4). ZBTB4 binds methylated CpGs, thereby repressing gene transcription (30), and plays a crucial role in oncogenesis (31). In our cDNA clone, a CpG-rich sequence was alternatively spliced into the 5’ UTR, and the immunogenic peptide M046 with the highly repetitive sequence 5’-GGAGGARAGAGAGAGAGGGQNRSGRGR-3’ was derived thereof. Alternative 5’ UTRs play an important role in posttranscriptional regulation, particularly in carcinogenesis (32, 33). Cryptic epitopes derived from 5’ UTRs are a unique possibility to provide the immune system with a danger signal in response to disease-associated deregulation of gene expression. Notably, several other peptide sequences in our analysis are rich in amino acids Ala, Arg, Gly, and Pro and are derived from GC-rich nucleotide sequences, including 5’UTRs.

Each cell, healthy or diseased, produces not only functional proteins from the correct ORF, but also concomitantly gives rise to aberrant translational products through various mechanisms. For example, ≤30% of newly synthesized polyptides have been shown to be defective ribosomal products resulting from premature termination or improper folding of the nascent protein (34, 35). A recent study of small proteins (≤20 kDa) in cell lines demonstrated that the use of alternative translation start sites may significantly enlarge the human proteome (36). Numerous transcriptional and translational molecular mechanisms have been summarized to give rise to peptides expressed in alternative reading frames (37, 38). In short, there is accumulating evidence...
that a significant portion of the proteome consists of presumably short-lived, low abundant products that are not encoded by the annotated coding sequences.

What can be considered as molecular junk is actually a vast source of alternative antigenic structures to be monitored by the different branches of the immune system. Even if expressed only in minute amounts, such Ags can efficiently induce antiviral or antitumor T cell immunity by serving as MHC class I ligands. Indeed, many cryptic CD8 T cell epitopes have been characterized in viral infections (39–41), as well as on tumor cells (37, 42–47). MHC class II ligands have been less extensively studied in the context of cancer immunity. Nevertheless, CD4 T cell clones specific for out-of-frame translated MHC class II ligands have been reported (48, 49). In contrast, a general role of cryptic epitopes as B cell epitopes has not been described so far. Clearly, the presence of high-titer circulating tumor-specific IgGs reflects a more comprehensive immune response to an Ag, because it is dependent on concomitant T cell activation.

The question is how cryptic epitopes, despite their low abundance, small size, and probably short-lived nature, can actually elicit an efficient humoral immune response. The final identification and characterization of cryptic epitopes will always be hampered by their low abundance. In light of their significant impact on humoral immune response in patients with cancer, better understanding of the transcriptional, translational, and presentation mechanisms of these gene products is needed. Deeper insight into these concepts can finally facilitate the future design of vaccines and immunotherapeutic strategies against cancer (38, 50, 51).

Acknowledgments

We thank Birgit Bette for excellent technical assistance and Jochen Imig and immunotherapeutic strategies against cancer (38, 50, 51).

References


Supplemental data 1

cDNA sequences of identified clones and the corresponding amino acid sequences of the displayed peptides. DNA/amino acid sequences of the Aga2p-protein are typeset in orange.

M004

L W P G G G G G R G R G G G G R G R G G G C A P R R T
TTATGGCCGGGAAGAGGAGGGCGCCGGGAGCAGGCGCGGGGGCCGGGAGCAGGCGGGCGGCTCCGGAA
GCTGCTGCCACGGACAGGACCTGAGGCGGGCGGCCCCGACCCCTGGGCCCCCGCTGCGGCCCCCGGCTGCG

M008

TTATGGCCGGGATGGGGGCGGCGGCCGCGGAGGCCAGGCCGGTGCCCTGCGGGGACGCCCAGCGCAGCCCAGCCC
R A A L P C A L P A L P A L P G A R P P R R I H V R
CGGCCAGCCCTGCCCTGGCCTGCCCCCTGCTGGCCCCGGGGGCCGCCGCCGCCAGGCCGCACCCGACTCCATGCTG
H H T P L W P E H A K Q L P I A P E T A A A A P A P
CACCACACCCACCTGGCCGGGAGGAGCCAGCTCCTCCCATGCCGCTCCGGAAGCGCTCAGCCTCCGCCCC
K P A P T *
AAGCCGGCCACCCACCTGACGCAAGCACCAGGACCACCAGTGGAGAAGGGATCAGATAGCTCCTCAGAGAAGGTTG
GCTACATGTATGcTGAGcCCACTTAATAAGcAGGGTAATGAGGACTTCCGAAAATgTTAAagAAAACttCCCAAG

M009

L W P G G G G G R G *
TTATGGCCGGGATGGAGGCGGAGGAGGCAGGTGAGTGATATGGTTTGTCTGCAGCCCCATCAAgTCTCA
ACTCGWWTTaTRTCTCCCGGwTTCCCATGTGCTGCTAGNGGGYCCCWGTGGGGGTTGTTACCTGCTGCTTGTGG
GCTCTTCTCCTGTCTHTHTCCTGTTTTGTGTTTTcCTGTCCTClwGDDGCTGTTGGGTTTNTCNGGTTTTCTGCTT
TGCTTCTTCTCCTCNTTTCCTGTTGGCHCCCCgCNTGTC

M017

L W P G A G G G G G S P *
TTATGGCCGGGAGGGCTGGGGGAGGGGGTGGTGGTGGTAGTCCCTGAGATACACTGGGAGGAGTGGCTACCTGC
ATGAGGCGACACTCTCTGTTGGAGATGCAAGGGGTAGGTGAGTGATATGTTTGTCTGCAAGGCCCCATCCAAgTCTCA
AAAGGAGCATGAACCAACCCACTGGGATATGGGAAGATATTCATAGGCTGGTGTTGTGCATTCATTTGCTGCATT
ACAtttCATTTTGGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT
GCTAGAAATCTGGCCAGTGagtttcCCCGCTTtaTTTTCATCCTCATCAGCTCAGCTGAGAGGAAATTTgTCTDCCTC
TCGTTAGTAGTAGTTTTGTTACATCTCTGCTGCGAAAGCTCTCTtCTCAACGGtCCAcCTGGATAGCAAgATGCTCATC
TCAANTCTATCGTCTGTTATCAATAGGAAGACTCCCTGTTTCCTTttTCGTTTTATGATTDCCTGCGNCCACAGACTTGAA
AG

M026
L W P G A G G G G G G G G N G H G G Q H V P G G R L R F * TTATGGCCCGGGGCGCGAGGCGGCGGCGGGAACGGCCATGGCGGCCAACATGTACCGGGTGGGAGATTACGTCTATTTTGAGAACTCTTCCAGCAATCCTTACCTGGTTAGACGGATTGAGGAGCTCAACAAGACTGCAAATGGAAATGGGGAGGCAAAGGTTGTCTGTCTTTTCCGGCGCAGGGACATTTCTAGTAGCTCAACAGCCTGGCTGATAGTAATGACACAGATATCCTGAGCAGATCCTGAGAATCGAGGCTGAGATCCCCAGATCGCCTAGTAGAGGGGAATGAAAAAGGAGGAATCAAAGCAGCCAGGGGGGTTGCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGAAGAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGGgGTGTCTGAGCAGCAGCGCCATCAACTGAAGCACCGGGAACTTTTTCTTTCTCGGCAATTTGAATCATTACCAGCCACCCCATACGGGGGAAATGCAGTGTGACCCTCTTGAATGACACAGATATCCTGAGTACCTGGAAAAGGAGGACTGCTTTTTTCTACCTGGTGTTTGACCCCGTGCAGAGACACTTCTCGCTGATCAGGGCGAGATTAGAGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGGAGAATCTGATAATCGGAACCAAGAAGATGGAGATGAAGGTCTGGGACCCAGAACACCCTTccACAAGGGGCCCCAGCAGGAGCCGCCTAGTAGAGGGAGGTTTGAAGAGGAATCAAAGCAGCCAGG
TTTGCTATTCTGTAGCTTTTACAMCATTTGTCTTCCAAAACTC

M061
L W P G G G G G A G N C K G T C K A N *
TTATGGCCGGGGGCGGGGGGCTGGCGGGGGAACTGTAAGGGAACATGTAAGGCTAATTAAGGTAACATCATCTGTT
AGGTGCTTTTTTTGTCTGTGTGTGTCTGATGAGGCCAATCTGAGAGGAGCCATAGAGGG
AACATGAGATACATGGCCTTCCCAAGGGCACTTTTGAGAAAAATACCTAATCTCTgCGACCTCAGTTTACTC
TTGTGCTCtATAGTGTTGTGTGAGAAAA gtAATCgTGTTGTAAGATGAATCTTACCATGGAGCTGTGAAGTGAGG
TCATTTCAAGAGAATGGGCTGCTCTNCTGCTTTAAACCAACCTCgC

M081
L W P G A G G G G G G P G A A D R R R R D K G A A A R
TTATGGCCGGGGGCGGGAGGCGGCGGCGGCCCGGGAGCTGCCGATCGGCGCCGGGACAAAGGCGCGGCCGCCCG
RPQ Q P E P G R T A G A Q R A P R R D *
CGCCCCCAGGCAGCCCGGGCAGGGCGACACCGCCGGGCGACGCGCCCGCCCGCGATGACTGATGTTTCC
ACAAAGCAGGCATTGGGCTCTTCGACACTACCCCCAGCAACTCgAAATTcACACCTGCgGACTGCAACGcAT
CAAAAGACGAAATTTCAGCTACTGCAAGcTCAGTACCACAGCCTcAAGcTcGAATGTGACAAGTTGGcCAGTGAGAA

P483.1
L W P G E S P F L P F S K K *
TTATGGCCGGGGGAAAGTCCTTTTTTGCCCTTTCTCCTCAAAAAATACCTTTCCACAGAGAACAACGTGCTCTTCTATC
CAGTTTTTATCTTTTATATAAAATATCAAAAGAAAAGCTGCAAGGGTTGCAAAAGGGCAGGGGCTGTGAGGAGAAGAAAAACACAG
CAGGGGAAACCCTTTTTTTTAACTCAATTGAGAATATGCTAATTTTTTTAACTCAGGAAATTGCTGATAICAA
TGCGACGTCTCAAGGCGTAACGAGGTCTCATTTTTTCTCACCATTAGGGGTATAGTTGGCTTGTGACTCCTGGA
ATCATTTTTACTGTGTTTGGTTTTATTTATCTTTAGTGCTTAATTAAAAAATAAAAATTTTTTTTTTTTTTTACCTGTAGTT
TCATTACCTTTTTGAAATAAGTGCTACACAAAAAATGTATTTTTTTTTTGTGCTGAGTGAATTTGATTTGTAGAT

P483.2
L W P G H G S A G D L G D Q Q Q R *
TTATGGCCGGGGCCATGGCAGGGCTGGGGAACTGGAGTGTCCTTGCTGTATCCCTGTTGTGAGGTTCCTTCCAGG
G W H *
Sequences of the three most abundant clones that were additionally identified after selection with Fab antibody B1

**B1-127 (37 clones)**

```
L W P G P L E A G E G G H P G D D R E T P A E P A
TTATGGCCGGGG
```

**B1-107 (9 clones)**

```
L W P G S G A E C P S S W E T G R G R K G G R P L
TTATGGCCGGGG
```

**B1-10 (4 clones)**

```
L W P G P N T C A R A P P P R R G R D G P V V
TTATGGCCGGGG
```
CATTGAGTPTAAACCCTGATCTGATAAACAAACATGATGATGAAACAAAATCGACTTTGTTCCACGTACTTT
TAGCTCGTACAAAATACAAATATACTTTTCTATTTCTCCGTAACAAACACACATGTATCTCTTTTCTAT
TTTTTGTTCCGGTTACCAACTTTTACATACTTTTTATATTGCTATTTCTACTTTTATACACTAAAAAACTAAGACAATT
TTATTTTGCTGCTTGCCATATTTCAATTGTATAATTTATTCTATATCTATTAGCTGTTAAAAGAT
GAATGTGAAATCGAATCTCTAGAGAAATGGCAGATGCACAAACAACTACTTAAATAATTACTACTCAGTAATAACCT
ATTTCTTAGCATTGGACCAATTTTGCTATTTTG
Supplemental Data 2

Cryptic epitope sequences on ENSEMBL-Transcripts including genetic variation. Sequences of cryptic epitopes are shown in red, alternative start codons in blue.

Key

<table>
<thead>
<tr>
<th>Codons</th>
<th>Alternating codons</th>
<th>Alternating codons</th>
<th>Alternative start codons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variations</td>
<td>3' UTR</td>
<td>5' UTR</td>
<td>frameshift coding</td>
</tr>
<tr>
<td>Non-synonymous coding</td>
<td>Regulatory region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other features</td>
<td>UTR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cryptic epitopes</td>
<td>cDNA-sequence</td>
<td>Peptide sequence</td>
<td></td>
</tr>
</tbody>
</table>

---

M004/ENST00000388824

```
1  ATGCCCAGCTGCTGCCCCAGCGGCCGCCGGCGGGCGGGCGGGCGGGCGGGGGCGGGGGCGGCGGGGGAGGACCCCGGACCC
91  GGACCTGCGCCCCCGCCCGAGGGCGCCCAGGAGGCCGCGCCCGCGCCCCGGCCGCCGCCCGAACCCGACGACGCGGCCGCCGCGCTCCGC
181  CTGGCGCTGGACCAGCTGTCGGCGCTCGGGCTGGGGGGCGCTGGCGACACGGACGAGGAGGGGGCGGCCGGGGACGGCGCAGCGGCGGCG
271  GGGGGCGCGGACGGCGGGGCGGCTCCGGAGCCTGTGCCCCCCGACGGACCTGAGGCCGGCGCGCCCCCGACCCTGGCCCCCGCCGTGGCC
361  CCCGGGTCGCTGCCGCTGCTGGACCCCAACGCGAGTCCCCCGCCGCCGCCGCCGCCCCGGCCGTCGCCCCCCGACGTGTTCGCGGGCTTC
451  GCGCCCCACCCCCGCGCCCTGCGCCCCACGATCGACCTGACGTGACCTCGAAGGTAACGCTAACATGCACGCCCAAGAAAGCTTACACATGCC
541  GAGTTGCTCCGCTGCCCCAGCTCCGAGCAGCTCGGAGATCGTGGTGGTCTGGCAGCGCTCAAGATCAAGCCTCCTGGGCCCAAGACAAC
631  ACCTACATCAAGACCCAGTGGCGCCGGCGGAGGAGGAGCTGCTGGATCTGCTGACCCTGGCAGCGAGGAGACACGACGTGGAGATGCAAGCT
721  CTGTCCGCGGCGGCCAGGCTTTCTGCATCCATGCGGCCACGCGAGAGCCGCGCCTGCTGGATCTGCTGACCCTGGCAGCGAGGAGACACGACGT
811  CCCGGGAGGACACCATCCTCGTGCCTGCCCCAGCTCCGAGCAGCTCGGAGATCGTGGTGGTCTGGCAGCGCTCAAGATCAAGCCTCCTGGGCCCAAGACAAC
```
M026/ ENST00000278823

1 TCCGGAAGGAGGCGAACCCTGAGGCGGGCCCGGCAAGCCTTCCCTGCGGCCGGCAGAGCCCAACGACTAGTGGGACTCCGCGGGGGCGGGY

91 Y                                    R

90 GGTAGCTGGAGCCTGGCTCTGGCCTGGCAGGAGCCGAGCTCGTTCCGGAAGAAGCCGAGCGGACGGGGGCCAGCCTCRGCGTCCCGGGAG

181 TGAGGCAGATAGCTGCGGCGGCGACAGCGCGGGCCGGGATGAACCGCGACGGCTGAGGCAGCGGAGGTGCCGGCTGCGCGGGCCCCAGTGA


271 GACTCCCTCGAAGCAGCCGCCACCCAGTTCCGGGGCTTTGCCTCGAGCCGAGCCCTGCCCCCGCGAGCCTCCCGGACCCCTTTGTGCGGCCG


361 GAGGCGCGCGGGCGAACGCGCGCGACAGCGCGGGCCGGGATGAACCGCGACGGCTGAGGCAGCGGAGGTGCCGGCTGCGCGGGCCCCAGTGA


541 GTTAGAAGATTTGAGAGGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGAGAATCTGATAATCGGAACCAGCAGAAG


631 AAGCAGCGCGAATTTTCTTTTCTTCTCGCAATTTGAATCATTACCAGCCACCCACATACGGGGGAAATGCAGTGTGACCTCTTGAATGAG


721 AGCAGACACGCCAGCTGCTGATAGTAATGCCAGGGAGTTTGAAGAGGAATCAAAGCAGCCAGGGRTGTCTGAGCAGCAGCGCCATCAACTG


811 CAGGGCGAGATTAGAGGTTGGTTGCAAATACCAAGCTGAGATCCCAGATCGCCTAGTAGAGGGAGAATCTGATAATCGGAACCAGCAGAAG


901 ATGGAGATGAAGGTCTGGGACCCAGACAACCCTCTCACAGACCGGCAGATCGACCAGTTTCTTGTGGTGGCCCGAGCTGTGGGAACCTTT


991 GCAGAGGCGTACGATGTTACGCTGAGCTCCCTGCAAGCAAGCTGATCCCGGACCGCACTTGCACCTGCTGCCCGGACCGCACTTGCACCTGCTG


1081 GCCATGGAATCCTGGACAAGGAGGAGGCTACCCAGCTGCTAGTAAAGCCATAGTCCAGGAGGCCACAGGAGGCCCAGTGCTGTGCTGCGAT


1171 GAGGAGATGAAGGTCTGGGACCCAGACAACCCTCTCACAGACCGGCAGATCGACCAGTTTCTTGTGGTGGCCCGAGCTGTGGGAACCTTT


1261 TTTGCTGCCAGATGCCCTGGCCAGATGCGCTCCCTGCAAGCAAGCTGATCCCGGACCGCACTTGCACCTGCTGCCCGGACCGCACTTGCACCTGCTG


1351 GTCGCTGGAACAGACAGCAGCACTGAAACAGCTGCTGCTGCTAGTAAAGCCATAGTCCAGGAGGCCACAGGAGGCCCAGTGCTGTGCTGCGAT

7921 GGTGTTCATAGGGGATTTTTGCTTTTTTAAGTTGATGATACAGGATATTTTCATTAAATTATATCATGCTTTATGACTTAAAT

Y

8011 ATTCAATTTATGACCTTGG

-------------